Wednesday, 17 Oct 2018

You are here

Immunophysiology of the Gout Attack

Gout may be an ancient disease, with arthritis of the big toe having been described in Egypt in 2,600 BC, but only now are the underlying pathophysiologic events being elucidated and understood.

Current thinking on the pathogenesis of gout, which today affects more than 8 million Americans -- 4% of the population -- has evolved into the "mobilization flare" hypothesis. In this disease conceptualization, when serum urate levels exceed 6 mg/dL, even in asymptomatic individuals, deposition of urate crystals in the synovium and other tissues begins.

"Gout represents the most hyperinflamed situation we know about," said Peter Lipsky, MD, from Charlottesville, Virginia, at the Florida Society of Rheumatology annual meeting.

Crystals of monosodium urate form in close proximity to each other and proteins and rapidly become an insoluble crystalline lattice structure, explained Lipsky, the former scientific director of NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland.

The surface of that structure is quite active and is in equilibrium with uric acid levels in surrounding tissues. But with sudden changes in the microenvironment, which could be the level of uric acid, pH, temperature, or changes in proteins that increase their solubility, the lattice matrix becomes unstable and crystals begin to shed off the surface into the surrounding tissue, he noted.

"If the shedding is relatively modest, with only a few crystals being released, those can be opsonized with a variety of positively charged proteins including ApoE and they do not become inflammatory," he said.

However, if a large mass of crystals is shed, the crystals can begin to interact with receptors on immune cells, the process of inflammation begins, and if the crystals are opsonized with immunoglobulin, the process is further heightened.

"It's a very dynamic process occurring at the surface of this crystalline lattice structure, and it's the additional proteins in the environment that seem to control whether or not the crystals are shed," he noted.

Further understanding of the underlying processing leading to gout derived from work initially done at the NIH among children with autoinflammatory diseases, in which a cellular structure known as the inflammasome was described, according to Lipsky.

The NLRP3 inflammasome is capable of sensing the presence of a variety of intracellular molecules and can lead to the induction of inflammatory responses. When the molecule is the monosodium urate crystal and not soluble monosodium urate, the multiprotein structure assembles and releases activated caspase-1, which is the critical enzyme involved in the processing of interleukins (IL) 1 and 18 and other proinflammatory molecules. This leads to the production and release from the cell of active IL-1 and IL-18 -- and the inflammatory response.

"This is the basis of how we now understand that urate crystals stimulate inflammation, and is also the basis of why the IL-1 blocker canakinumab [Ilaris] seems to be so effective in controlling inflammation in gout," he concluded.

Dr. Lipsky disclosed a relevant relationships with Horizon Pharma.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Allopurinol Shown to be Renal Protective

Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.

Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid

The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC. 

Usual Allopurinol Doses Insufficient in CKD Patients

Uric acid (sUA) control may be a challenge in patients with chronic kidney disease (CKD). A cohort study shows that conventional dosing recommendations for allopurinol are unlikely to reach target serum sUA goals.

Sleep Apnea Raises Gout Risk

Patients with obstructive sleep apnea were at increased risk for incident gout, particularly in the first years after the sleep apnea diagnosis, U.K. researchers reported.

In a large retrospective cohort study, the adjusted hazard ratio for a new gout diagnosis among individuals with sleep apnea was 1.42 (95% CI 1.29-1.56), according to Milica Blagojevic-Bucknall, PhD, of Keele University in Keele, England, and colleagues.

Adherence to Gout Therapies Painfully Low

A retrospective study of the large UK Clinical Practice Research Datalink assessed patient compliance in gout and found that adherence to allopurinol is poor, especially among females and younger patients and those with fewer comorbidities.